BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33201882)

  • 1. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
    Flint L; Korkegian A; Parish T
    PLoS One; 2020; 15(11):e0239354. PubMed ID: 33201882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
    Tonge PJ; Kisker C; Slayden RA
    Curr Top Med Chem; 2007; 7(5):489-98. PubMed ID: 17346194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
    Bonnett SA; Dennison D; Files M; Bajpai A; Parish T
    PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
    Vilchèze C; Baughn AD; Tufariello J; Leung LW; Kuo M; Basler CF; Alland D; Sacchettini JC; Freundlich JS; Jacobs WR
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3889-98. PubMed ID: 21628538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery.
    Prasad MS; Bhole RP; Khedekar PB; Chikhale RV
    Bioorg Chem; 2021 Oct; 115():105242. PubMed ID: 34392175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
    Encinas L; O'Keefe H; Neu M; Remuiñán MJ; Patel AM; Guardia A; Davie CP; Pérez-Macías N; Yang H; Convery MA; Messer JA; Pérez-Herrán E; Centrella PA; Alvarez-Gómez D; Clark MA; Huss S; O'Donovan GK; Ortega-Muro F; McDowell W; Castañeda P; Arico-Muendel CC; Pajk S; Rullás J; Angulo-Barturen I; Alvarez-Ruíz E; Mendoza-Losana A; Ballell Pages L; Castro-Pichel J; Evindar G
    J Med Chem; 2014 Feb; 57(4):1276-88. PubMed ID: 24450589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
    Matviiuk T; Mori G; Lherbet C; Rodriguez F; Pasca MR; Gorichko M; Guidetti B; Voitenko Z; Baltas M
    Eur J Med Chem; 2014 Jan; 71():46-52. PubMed ID: 24269516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis.
    Early JV; Mullen S; Parish T
    PLoS One; 2019; 14(10):e0222970. PubMed ID: 31589621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel MenA Inhibitors Are Bactericidal against
    Berube BJ; Russell D; Castro L; Choi SR; Narayanasamy P; Parish T
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962346
    [No Abstract]   [Full Text] [Related]  

  • 11. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of compound kill kinetics against Mycobacterium tuberculosis.
    Early J; Alling T
    Methods Mol Biol; 2015; 1285():269-79. PubMed ID: 25779322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
    Robertson GT; Ektnitphong VA; Scherman MS; McNeil MB; Dennison D; Korkegian A; Smith AJ; Halladay J; Carter DS; Xia Y; Zhou Y; Choi W; Berry PW; Mao W; Hernandez V; Alley MRK; Parish T; Lenaerts AJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
    Pajk S; Živec M; Šink R; Sosič I; Neu M; Chung CW; Martínez-Hoyos M; Pérez-Herrán E; Álvarez-Gómez D; Álvarez-Ruíz E; Mendoza-Losana A; Castro-Pichel J; Barros D; Ballell-Pages L; Young RJ; Convery MA; Encinas L; Gobec S
    Eur J Med Chem; 2016 Apr; 112():252-257. PubMed ID: 26900657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
    Larsen MH; Vilchèze C; Kremer L; Besra GS; Parsons L; Salfinger M; Heifets L; Hazbon MH; Alland D; Sacchettini JC; Jacobs WR
    Mol Microbiol; 2002 Oct; 46(2):453-66. PubMed ID: 12406221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.